Search Results for 'biosimilar'
biosimilar published presentations and documents on DocSlides.
MODULE 8. Follow-on drugs: generic, biosimilar
by alida-meadow
& non-biological similar medicinal products ....
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
U.S. Biosimilars: An Introduction
by calandra-battersby
Disclaimers. :. By 2016, 7 of the top 10 pharmace...
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilar Biological Products
by luanne-stotts
2016 . Clinical Investigator . Training Course. S...
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Applying Biosimilars in Hematologic Cancers
by conchita-marotz
This program will include a discussion of off-lab...
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges. Â . Introduction. Diff...
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
by carla
Adoption by CHMP for release for consultation24 Ma...
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
 What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
PhAMA Position on Biosimilar Medicines Ms. Leah
by conchita-marotz
PhAMA Position on Biosimilar Medicines Ms. Leah Go...
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
by alida-meadow
Richard Montes, Ph.D.. Hospira. , a Pfizer compan...
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Biosimilars in the united states – Update on FDA Impleme
by test
James C. Shehan. Hyman, Phelps & McNamara, P....
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
by anastasia
x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...
Improving Your Formulary and Denials Management
by trinity
Zinkeng Asonganyi, PharmD. Director of Pharmacy Se...
